Intratumoral Injection of mRNA-2752 and Pembrolizumab for High-Risk Ductal Carcinoma In Situ

Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology

William J. Gradishar, Meena S. Moran, Jame Abraham et al. · Journal of the National Comprehensive Cancer Network · 2022 · 937 citations · Full text

Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer

Rita Nanda, Minetta C. Liu, Christina Yau et al. · JAMA Oncology · 2020 · 672 citations · Full text

Breast Cancer Mortality After a Diagnosis of Ductal Carcinoma In Situ

Steven A. Narod, Javaid Iqbal, Vasily Giannakeas et al. · JAMA Oncology · 2015 · 608 citations · Full text

Durable anticancer immunity from intratumoral administration of IL-23, IL-36γ, and OX40L mRNAs

Susannah L. Hewitt, Ailin Bai, D. R. Shackleton Bailey et al. · Science Translational Medicine · 2019 · 286 citations

A population-based validation study of the DCIS Score predicting recurrence risk in individuals treated by breast-conserving surgery alone

Eileen Rakovitch, Sharon Nofech‐Mozes, Wedad Hanna et al. · Breast Cancer Research and Treatment · 2015 · 231 citations · Full text